CMTM5 Antibody

What is CMTM5 and what role does it play in prostate cancer?

CMTM5 (CKLF-like Marvel transmembrane domain containing family member 5) is a tumor suppressor gene first reported by the Human Disease Gene Research Center of Beijing University in 2003. It contains a MARVEL domain that may regulate transmembrane signaling . In prostate cancer, CMTM5 expression is significantly downregulated in cancer tissues compared to normal prostate tissues, while EGFR expression is significantly upregulated . Research indicates that CMTM5 significantly inhibits tumor cell proliferation, adhesion, and migration . The protein has been shown to suppress prostate cancer development by downregulating EGFR and PI3K/AKT signaling pathway components, making it particularly relevant for castration-resistant prostate cancer (CRPC) .

What methods are most effective for detecting CMTM5 expression in tissue samples?

For effective detection of CMTM5 in tissue samples, immunohistochemistry (IHC) is the gold standard approach. Tissues should be fixed in 4% paraformaldehyde for 24 hours at room temperature, embedded in paraffin, and sectioned to 4-5 μm thickness . Antigen retrieval requires boiling samples in EDTA buffer (pH 9.0) at 120°C for 2 minutes followed by cooling to room temperature for 30 minutes . To quench endogenous peroxidase, sections should be soaked in 3% peroxide solution for 15 minutes .

For protein quantification, western blotting can be used with appropriate CMTM5 antibodies. Detection should employ an ECL western blotting system following manufacturer's protocols . For scoring IHC results, calculate the CMTM5 score by multiplying the percentage of positive cells (0, <10%; 1, 10-24%; 2, 25-50%; and 3, >50%) by staining intensity (0, no staining; 1, weak; 2, moderate; 3, strong), with high expression defined as a total score ≥4 .

How does CMTM5 interact with and regulate the EGFR signaling pathway?

CMTM5 appears to regulate EGFR signaling in a manner similar to other CMTM family members. Research demonstrates that CMTM5-v1 attenuates EGF-induced receptor signaling by repressing EGFR and Akt phosphorylation in prostate cancer cells . Specifically, ectopic expression of CMTM5-v1 suppresses cell proliferation, migration, and p-EGFR levels .

Immunofluorescence analysis reveals that CMTM5 overexpression leads to negative expression of p-EGFR in cells, while vector control cells show positive expression . This interaction appears to be mechanistically similar to how CMTM7 and CMTM8 regulate EGFR - by promoting receptor internalization and subsequent degradation, thus suppressing downstream signaling . The MARVEL domain within CMTM5 likely plays a key role in this membrane protein interaction .

What are the experimental approaches for studying CMTM5's effect on cell proliferation and migration?

To evaluate CMTM5's effects on cell proliferation, researchers should consider the following approaches:

• Cell Counting Kit-8 (CCK-8) assay: Effective for evaluating proliferation rates of CMTM5-overexpressing cells compared to vector control cells .

• Colony formation assay: Measures colony-forming capacity by counting colonies with ≥50 cells .

• Migration assessment via:

  • Wound healing assay to measure scratch closure rate over time

  • Transwell migration assay to quantify cell migration through membranes

  • Transwell invasion assay to evaluate invasive capacity

For EGF-induced proliferation studies, cells should be maintained in culture media supplemented with 1% FBS in the presence or absence of 20 ng/ml EGF after CMTM5 transfection . For chemotactic migration assessment, transwell chamber assays with EGF as a chemoattractant provide valuable insights into CMTM5's regulatory effects .

What prostate cancer cell line models are most appropriate for CMTM5 research?

Based on the literature, the following cell lines are most appropriate for CMTM5 research:

• DU145 cells: A castration-resistant prostate cancer cell line with high EGFR expression and undetectable CMTM5, making it ideal for CMTM5 overexpression studies .

• PC3 cells: Another metastatic CRPC cell line with upregulated EGFR and downregulated CMTM5, suitable for studying CMTM5's tumor suppressive functions .

These cell lines are particularly valuable because they represent castration-resistant prostate cancer, where EGFR signaling plays a crucial role in disease progression. Additionally, the absence of endogenous CMTM5 expression makes them excellent models for gain-of-function studies through lentivirus-mediated CMTM5 overexpression .

What are the molecular mechanisms by which CMTM5 inhibits the PI3K/AKT signaling pathway?

CMTM5 inhibits the PI3K/AKT signaling pathway through multiple interconnected mechanisms:

• Direct impact on pathway components: Western blotting analysis reveals that CMTM5 overexpression downregulates protein expression levels of p-AKT, AKT, and PI3K .

• EGFR-mediated regulation: CMTM5 attenuates EGF-induced receptor signaling by repressing EGFR phosphorylation, which consequently reduces Akt phosphorylation in prostate cancer cells .

• Synergistic effects with AKT inhibitors: CMTM5-overexpressing cells show enhanced apoptosis when treated with the AKT inhibitor MK-2206, suggesting that CMTM5 sensitizes cells to AKT pathway inhibition .

This inhibition of the PI3K/AKT pathway is central to CMTM5's tumor suppressive functions, as this pathway plays a critical role in regulating cell proliferation and survival . The phosphorylation of PI3K activates AKT phosphorylation, and CMTM5's ability to disrupt this cascade appears to be a key mechanism underlying its anti-cancer effects .

What techniques should be employed to successfully overexpress CMTM5 in prostate cancer cell lines?

Successful overexpression of CMTM5 in prostate cancer cell lines requires:

• Lentiviral vector construction: The research indicates successful use of lentiviral vectors for stable CMTM5 overexpression in DU145 cells .

• Transfection verification: Western blot analysis should be employed to confirm CMTM5 protein expression in transfected cells compared to vector control cells .

• Selection methodology: Though not explicitly stated in the search results, standard lentiviral protocols typically involve antibiotic selection (often puromycin) to generate stable cell lines.

• Expression optimization: For studies requiring temporary expression, transient transfection with plasmids containing CMTM5-v1 is effective, as demonstrated in PC3 and DU145 cells .

• Validation: Functional validation through proliferation, migration, and signaling assays is essential to confirm that the overexpressed CMTM5 is biologically active .

The lentivirus-mediated approach appears particularly effective for establishing stable CMTM5 expression in prostate cancer cells that naturally lack CMTM5 expression .

How does CMTM5 regulate epithelial-mesenchymal transition (EMT) in prostate cancer cells?

CMTM5 appears to inhibit epithelial-mesenchymal transition (EMT) in prostate cancer cells through:

• E-cadherin regulation: Immunofluorescence analysis demonstrates that CMTM5 overexpression leads to significant upregulation of E-cadherin expression compared to control groups . Since E-cadherin is a critical epithelial marker whose loss is associated with EMT, this upregulation suggests CMTM5 helps maintain epithelial phenotype.

• EGFR signaling inhibition: By reducing p-EGFR levels, CMTM5 likely inhibits EGFR-induced EMT . EGFR signaling is a known promoter of EMT in various cancers.

• PI3K/AKT pathway suppression: As the PI3K/AKT pathway is a major driver of EMT, CMTM5's ability to inhibit this pathway likely contributes to its anti-EMT effects .

The research suggests that CMTM5 may inhibit metastasis of prostate cancer partly through these effects on EMT marker proteins, presenting a potential mechanism for its observed inhibition of cell migration and invasion .

What is the relationship between CMTM5 expression and sensitivity to tyrosine kinase inhibitors like Gefitinib?

CMTM5 appears to enhance sensitivity to tyrosine kinase inhibitors (TKIs) like Gefitinib:

• Increased drug sensitivity: Research demonstrates that CMTM5-v1 can promote the sensitivity of PC3 cells to Gefitinib, a TKI targeting EGFR .

• Mechanism of sensitization: This likely occurs through CMTM5's ability to attenuate EGFR signaling. By reducing EGFR and AKT phosphorylation, CMTM5 may make cells more vulnerable to further EGFR inhibition by Gefitinib .

• Potential clinical implications: The findings suggest that CMTM5 might be associated with the efficacy of TKIs through its potent inhibition of EGFR and potentially HER2 activation .

This relationship between CMTM5 and TKI sensitivity could have significant implications for prostate cancer treatment strategies, particularly for castration-resistant prostate cancer where EGFR signaling is often deregulated .

What are the differences between CMTM5 variants and their functional implications?

The search results specifically mention CMTM5-v1, which appears to be a variant of CMTM5:

• CMTM5-v1 function: This variant demonstrates tumor suppressor properties through inhibition of cell proliferation and migration by suppressing EGFR signaling .

• Regulatory capacity: CMTM5-v1 can attenuate EGF-induced receptor signaling by repressing EGFR and Akt phosphorylation in prostate cancer cells .

• Therapeutic implications: CMTM5-v1 can enhance the sensitivity of PC3 cells to Gefitinib, suggesting potential therapeutic applications .

While the search results focus primarily on CMTM5-v1, they don't explicitly describe other variants or comparative functional differences between variants. The research does note that CMTM5 was first reported in 2003, suggesting it may have been studied in various forms since then . Further investigation would be needed to fully characterize all CMTM5 variants and their distinct functional implications.

What methodological challenges exist in assessing CMTM5's interactions with other signaling molecules?

Key methodological challenges in studying CMTM5's molecular interactions include:

• Membrane protein complexity: As CMTM5 contains a MARVEL domain associated with membrane-spanning regions, standard protein interaction techniques may require modification for these transmembrane proteins .

• Low endogenous expression: The downregulation or absence of CMTM5 in prostate cancer cells necessitates overexpression systems, which may not perfectly recapitulate physiological interactions .

• Pathway overlap: The PI3K/AKT pathway interfaces with multiple signaling cascades, making it challenging to isolate CMTM5-specific effects from broader cellular responses .

• Temporal dynamics: EGF signaling involves rapid phosphorylation events, requiring careful time-course experiments to fully characterize CMTM5's regulatory effects .

To address these challenges, researchers should consider combinatorial approaches including co-immunoprecipitation, proximity ligation assays, and real-time measurements of phosphorylation dynamics following CMTM5 manipulation.

What approaches can be used to study the differential expression of CMTM5 between normal and cancerous tissues?

To investigate differential CMTM5 expression between normal and cancerous tissues, researchers should consider:

• Paired tissue analysis: Collect PCa tissues and paired adjacent normal prostate tissues (as done with 70 patients in one study) to enable direct comparisons within the same individuals .

• Multi-method validation: Employ immunohistochemistry, RT-qPCR, and western blotting in parallel to confirm expression differences at both mRNA and protein levels .

• Quantitative scoring systems: Implement standardized scoring systems for immunohistochemistry (percentage of positive cells × staining intensity, with scores ranging from 0-9) to objectively assess expression levels .

• Comparative analysis of cell lines: Compare expression between non-cancerous prostate cells and various prostate cancer cell lines, particularly those representing different disease stages .

• Correlation analysis: Investigate the inverse relationship between CMTM5 and EGFR expression to better understand regulatory mechanisms .

These approaches can provide comprehensive insights into the downregulation of CMTM5 in prostate cancer and its potential implications for disease progression and treatment strategies.